Diseases / Uveal Melanoma
Uveal Melanoma Clinical Trials
DiseaseUveal melanoma is a rare primary intraocular cancer arising from melanocytes in the uveal tract (iris, ciliary body, or choroid). It is the most common primary malignant intraocular tumor in adults.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow Uveal Melanoma
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma NCT07804186 | Phase 3 | Recruiting | IDEAYA Biosciences | Started 2026-09 |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma NCT07015190 | Phase 3 | Recruiting | IDEAYA Biosciences | Started 2026-01 |
| Adjuvant Tebentafusp in High Risk Ocular Melanoma NCT06246149 | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | Started 2024-11 |
| PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases NCT06519266 | Phase 3 | Recruiting | Vastra Gotaland Region | Started 2024-06 |
| Adjuvant Melatonin for Uveal Melanoma NCT05502900 | Phase 3 | Recruiting | Gustav Stalhammar | Started 2022-10 |
Recently started
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma NCT07747935 | Phase 1/2 | Not yet recruiting | ReBio Pharma | Started 2026-10 |
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma NCT07804186 | Phase 3 | Recruiting | IDEAYA Biosciences | Started 2026-09 |
| A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors NCT07636785 | Phase 1/2 | Recruiting | VM Discovery, Inc. | Started 2026-07 |
| Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma NCT07501117 | Phase 1 | Recruiting | Inge Marie Svane | Started 2026-06 |
| A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma NCT07338968 | Phase unknown | Enrolling by invitation | Aura Biosciences | Started 2026-03 |
Results recently posted
| Trial | Phase | Status | Sponsor | Results posted |
|---|---|---|---|---|
| Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma NCT02678572 | Phase 3 | Completed | Delcath Systems Inc. | Results posted 2026-09-10 |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases NCT02858869 | Phase 1 | Completed | Emory University | Results posted 2026-03-09 |
| KZR-261 in Subjects With Advanced Solid Malignancies NCT05047536 | Phase 1 | Terminated | Kezar Life Sciences, Inc. | Results posted 2025-12-19 |
| SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver NCT01473004 | Phase 2 | Completed | Thomas Jefferson University | Results posted 2025-11-14 |
| Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma NCT03712904 | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Results posted 2025-09-24 |
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Unknown | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | — | — | 2 | 1 | — | — | — | 3 |
| Phase 1 | 7 | 2 | — | 6 | 34 | 12 | — | 2 | — | — | 63 |
| Phase 1/2 | 10 | 1 | 1 | 5 | 6 | 4 | 2 | 4 | — | — | 33 |
| Phase 2 | 6 | 1 | — | 12 | 57 | 12 | 3 | 6 | — | — | 97 |
| Phase 2/3 | 1 | — | — | 1 | — | — | — | 1 | — | — | 3 |
| Phase 3 | 5 | — | — | 2 | 8 | 2 | — | 1 | — | — | 18 |
| Phase 4 | — | — | — | — | — | — | — | 2 | — | — | 2 |
| Not applicable | 4 | — | — | 1 | 9 | 2 | 1 | 2 | — | — | 19 |
| Unknown | 4 | — | 1 | 6 | 12 | 2 | 2 | 11 | 1 | 1 | 40 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Uveal Melanoma | 3 | 63 | 33 | 97 | 3 | 18 | 2 | 19 | 40 | 278 |
| Melanoma | 1 | 39 | 21 | 45 | 3 | 3 | — | 3 | 8 | 123 |
| Neoplasm Metastasis | — | 11 | 5 | 9 | 1 | 3 | — | 1 | 2 | 32 |
| Neoplasms | 1 | 9 | 2 | 3 | — | — | — | 1 | — | 16 |
| Eye Neoplasms | — | 1 | 4 | 5 | — | 1 | — | — | 3 | 14 |
| Carcinoma, Renal Cell | 1 | 6 | 1 | 2 | — | — | — | — | 3 | 13 |
| Carcinoma, Non-Small-Cell Lung | 1 | 7 | 2 | 1 | — | — | — | — | 1 | 12 |
| Breast Neoplasms | 1 | 9 | 1 | — | — | — | — | — | — | 11 |
| Carcinoma, Hepatocellular | 1 | 6 | 1 | 2 | — | — | — | — | 1 | 11 |
| Sarcoma | 1 | 5 | — | 3 | — | — | — | — | 1 | 10 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Cancer Institute (NCI) | 22 | 1 |
| 2 | Institut Curie | 13 | 1 |
| 3 | Memorial Sloan Kettering Cancer Center | 11 | 0 |
| 4 | M.D. Anderson Cancer Center | 8 | 0 |
| 5 | Aura Biosciences | 7 | 1 |
| 6 | H. Lee Moffitt Cancer Center and Research Institute | 7 | 0 |
| 7 | Jonsson Comprehensive Cancer Center | 6 | 0 |
| 8 | University of Southern California | 6 | 0 |
| 9 | Vastra Gotaland Region | 6 | 1 |
| 10 | Delcath Systems Inc. | 5 | 3 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Ipilimumab | 29 |
| 2 | Nivolumab | 23 |
| 3 | pembrolizumab | 14 |
| 4 | Cyclophosphamide | 10 |
| 5 | incomplete Freund's adjuvant | 10 |
| 6 | Interleukin-2 | 9 |
| 7 | Melphalan | 9 |
| 8 | CTLA-4 Antigen | 8 |
| 9 | Dacarbazine | 7 |
| 10 | MART-1 Antigen | 7 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT07076550 Terminated | Terminated | Due to a strategic decision to re-prioritize the sponsor's existing portfolio. | 2026-07-09 |
| NCT03746431 Terminated | Terminated | A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175. | 2025-12-03 |
| NCT03865212 Terminated | Terminated | Lack of funding; lack of objective response | 2025-10-12 |
| NCT05308901 Terminated | Terminated | PI opted to close study due to poor accrual. | 2025-08-11 |
| NCT03417739 Terminated | Terminated | This was a Simon two stage design trial that terminated after the first stage due to lack of response. | 2025-07-16 |
| NCT05576077 Terminated | Terminated | Sponsor decision | 2025-02-24 |
| NCT05047536 Terminated | Terminated | Sponsor decision. | 2025-01-17 |
| NCT04935229 Terminated | Terminated | The decision was made to terminate the study after the completion of Phase 1 enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns. | 2024-07-17 |
| NCT05341349 Terminated | Terminated | Slow accrual | 2024-05-31 |
| NCT04720417 Terminated | Terminated | Trial enrollment was stopped early by study sponsors (before the anticipated accrual of 18 patients) due to no patients having significant reduction in disease. | 2024-04-30 |
Evidence
- Results reported
- 46.8%59 of 126 completed
- Published
- 17.5%22 of 126 completed
- Primary endpoint met
- 16.7%1 of 6 analyses
- Median months to report
- 25
Documents disclosed
Trial profile
- Median enrollment
- 40
- Median duration
- 58months
- Countries
- 30
- Study sites
- 1271
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 6
- Phase 1
- 25
- Phase 1/2
- 36
- Phase 2
- 34
- Phase 2/3
- 280
- Phase 3
- 108
- Phase 4
- 225
- Not applicable
- 50
- Unknown
- 100
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 53 |
| 2 | Philadelphia | United States | 44 |
| 3 | Houston | United States | 42 |
| 4 | Los Angeles | United States | 39 |
| 5 | Boston | United States | 30 |
| 6 | Nashville | United States | 29 |
| 7 | Tampa | United States | 25 |
| 8 | Paris | France | 24 |
| 9 | Chicago | United States | 20 |
| 10 | Cleveland | United States | 18 |